MicroRNA-219-5p functions as a tumor suppressor partially by targeting platelet-derived growth factor receptor alpha in colorectal cancer

Neoplasma

Volumn 62, Issue 6, 2015, Pages 855-863

  Xiong, G B ^a   Zhang, G N ^a   Xiao, Y ^a   Niu, B Z ^a   Qiu, H Z ^a   Wu, B ^a   Lin, G L ^a   You, L ^a   Shu, H ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Colorectal cancer; microRNA; miR 219 5p; PDGFR ; PI3K Akt

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; MICRORNA; MICRORNA 219 5P; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84969670595     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_104     Document Type: Article

References (49)

1. BRENNER H, KLOOR M, POX CP Colorectal cancer. Lancet. 2014; 383: 1490-502. http://dx.doi.org/10.1016/ S0140-6736(13)61649-9
2. SIEGEL R, MA J, ZOU Z, JEMAL A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29. http://dx.doi.org/10.3322/ caac.21208
3. FEARON ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6: 479-507. http://dx.doi.org/10.1146/ annurev-pathol-011110-130235
4. VENKATACHALAM R, LIGTENBERG MJ, HOOG-ERBRUGGE N, DE BRUIJN DR, KUIPER RP, et al. The epigenetics of (hereditary) colorectal cancer. Cancer Genet Cytogenet. 2010; 203: 1-6. http://dx.doi.org/10.1016/j.cancergencyto.2010.08.013
5. WALTHER A, JOHNSTONE E, SWANTON C, MIDGLEY R, TOMLINSON I, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009; 9: 489-99. http://dx.doi.org/10.1038/nrc2645
6. BARTEL DP MicroRNAs Genomics, Biogenesis, Mechanism, and Function. Cell. 2004; 116: 281-97. http://dx.doi. org/10.1016/S0092-8674(04)00045-5
7. CARTHEW RW, SONTHEIMER EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136: 642-55. http:// dx.doi.org/10.1016/j.cell.2009.01.035
8. FILIPOWICZ W, BHATTACHARYYA SN, SONENBERG N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9: 102-14. http://dx.doi.org/10.1038/nrg2290
9. AMBROS V. MicroRNA Pathways in Flies and Worms. Cell. 2003; 113: 673-6. http://dx.doi.org/10.1016/S0092-8674-(03)00428-8
10. CALIN GA, CROCE CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-66. http://dx.doi. org/10.1038/nrc1997
11. CROCE CM. Causes and consequences of microRNA dys-regulation in cancer. Nat Rev Genet. 2009; 10: 704-14. http:// dx.doi.org/10.1038/nrg2634
12. SHENOUDA SK, ALAHARI SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009; 28: 369-78. http://dx.doi.org/10.1007/s10555-009 -9188-5
13. BARANWAL S, ALAHARI SK. miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2010; 126: 1283-90. http://dx.doi.org/10.1002/ijc.25014
14. LEE YS, DUTTA A. MicroRNAs in Cancer. Annu Rev Pathol. 2009; 4: 199-227. http://dx.doi.org/10.1146/annurev. pathol.4.110807.092222
15. SLABY O, SVOBODA M, MICHALEK J, VYZULA R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009; 8: 102. http:// dx.doi.org/10.1186/1476-4598-8-102
16. BOARD R, JAYSON GC. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat. 2005; 8: 75-83. http://dx.doi.org/10.1016/j.drup.2005.03.004
17. FAROOQI AA, WASEEM S, RIAZ AM, DILAWAR BA, MUKHTAR S, et al. PDGF: the nuts and bolts of signalling toolbox. Tumour Biol. 2011; 32: 1057-70. http://dx.doi. org/10.1007/s13277-011-0212-3
18. HELDIN CH, OSTMAN A, RONNSTRAND L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998; 1378: F79-113. http://dx.doi.org/10.1016/ s0304-419x(98)00015-8
19. WEHLER TC, FRERICHS K, GRAF C, DRESCHER D, SCHIMANSKI K, et al. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer a possible rationale for a molecular targeting strategy. Oncol Rep. 2008; 19: 697-704.
20. KITADAI Y, SASAKI T, KUWAI T, NAKAMURA T, BUCANA CD, et al. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer. 2006; 119: 2567-74. http://dx.doi.org/10.1002/iic.22229
21. SCHIMANSKI CC, ZIMMERMANN T, SCHMIDTMANN I, GOCKEL I, LANG H, et al. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. Int J Colorectal Dis. 2010; 25: 181-6. http://dx.doi.org/10.1007/s00384-009-0843-7
22. KITADAI Y, SASAKI T, KUWAI T, NAKAMURA T, BUCANA CD, et al. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis ofhuman colon carcinoma. Am J Pathol. 2006; 169: 2054-65. http://dx.doi.org/10.2353/aipath.2006.060653
23. GUO FJ, ZHANG WJ, LI YL, LIU Y, LI YH, et al. Expression and functional characterization of platelet-derived growth factor receptor-like gene. World J Gastroenterol. 2010; 16: 1465. http://dx.doi.org/10.3748/wig.v16.i12.1465
24. CAPDEVILA J, MENDEZ G, MACARULLA T, RAMOS FJ, CASADO E, et al. New approaches and targets in advanced colorectal cancer: the molecular targets era. Expert Rev Anticancer Ther. 2007; 7: 1027-41. http://dx.doi. org/10.1586/14737140.7.7.1027
25. GROTHEY A, VAN CUTSEM E, SOBRERO A, SIENA S, FALCONE A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381: 303-12. http://dx.doi.org/10.1016/ S0140-6736(12)61900-X
26. HUANG N, LIN J, RUAN J, SU N, QING R, et al. MiR-219 -5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 2012; 586: 884-91. http:// dx.doi.org/10.1016/i.febslet.2012.02.017
27. RAO SA, ARIMAPPAMAGAN A, PANDEY P, SANTOSH V, HEGDE AS, et al. miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PloS one. 2013; 8: e63164. http://dx.doi.org/10.1371/i ournal.p one.0063164
28. HUANG C, CAI Z, HUANG M, MAO C, ZHANG Q, et al. miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α. J Clin Endocrinol Metab. 2015; 100: E204-13. http://dx.doi.org/10.1210/ic.2014-2883
29. LAHDAOUI F, DELPU Y, VINCENT A, RENAUD F, MESSAGER M, et al. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene. 2015; 34: 780-8. http://dx.doi. org/10.1038/onc.2014.11
30. LEI H, ZOU D, LI Z, LUO M, DONG L, et al. MicroRNA-219 -2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation. PloS one. 2013; 8: e60369. http://dx.doi.org/10.1371/iournal.pone.0060369
31. PARDINI B, ROSA F, NACCARATI A, VYMETALKOVA V, YE Y, et al. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients. Carcinogenesis. 2015; 36: 82-6. http://dx.doi.org/10.1093/carcin/ bgu224
32. CRAVEN RJ, XU LH, WEINER TM, FRIDELL YW, DENT GA, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 1995; 60: 791-7. http://dx.doi. org/10.1002/iic.2910600611
33. ZHU HT, HAN J, MA L. Expression and clinical significance of PDGFRalpha and PDGFRbeta in colorectal cancer. Ai Zheng. 2008; 27: 654-60.
34. LIU C, LI J, XIANG X, GUO L, TU K, et al. PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors. Am J Physiol Gastrointest Liver Physiol. 2014; 307: G749-59. http://dx.doi.org/10.1152/aipgi.00138.2014
35. KAULFUSS S, SEEMANN H, KAMPE R, MEYER J, DRESSEL R, et al. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells. Oncotarget. 2013; 4: 1037-49. http://dx.doi.org/10.18632/ oncotarget.1085
36. YUGE R, KITADAI Y, SHINAGAWA K, ONOYAMA M, TANAKA S, et al. mTOR and PDGF pathway blockade inhibits liver metastasis of colorectal cancer by modulating the tumor microenvironment. Am J Pathol. 2015; 185: 399-408. http://dx.doi.org/10.1016/i.aipath.2014.10.014
37. SUMAZIN P, YANG X, CHIU HS, CHUNG WJ, IYER A, et al. An extensive microRNA-mediated network of RNA- RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011; 147: 370-81. http://dx.doi. org/10.1016/i.cell.2011.09.041
38. GENOVESE G, ERGUN A, SHUKLA SA, CAMPOS B, HANNA J, et al. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-beta signaling in glioblastoma. Cancer discovery. 2012; 2: 736-49. http:// dx.doi.org/10.1158/2159-8290.CD-12-0111
39. LI Y, GUESSOUS F, ZHANG Y, DIPIERRO C, KEFAS B, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009; 69: 7569-76. http:// dx.doi.org/10.1158/0008-5472.CAN-09-0529
40. SILBER J, JACOBSEN A, OZAWA T, HARINATH G, PEDRAZA A, et al. miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PloS one. 2012; 7: e33844. http:// dx.doi.org/10.1371/iournal.pone.0033844
41. PAPAGIANNAKOPOULOS T, FRIEDMANN-MORVINSKI D, NEVEU P, DUGAS JC, GILL RM, et al. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene. 2012; 31: 1884-95. http://dx.doi. org/10.1038/onc.2011.380
42. GUAN H, WEI G, WU J, FANG D, LIAO Z, et al. Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab. 2013; 98: E1334-44. http://dx.doi. org/10.1210/ic.2013-1053
43. SCHMIDT Y, SIMUNOVIC F, STRASSBURG S, PFEIFER D, STARK GB, et al. miR-126 regulates platelet-derived growth factor receptor-α expression and migration of primary human osteoblasts. Biol Chem. 2015; 396: 61-70. http://dx.doi. org/10.1515/hsz-2014-0168
44. HEINRICH MC, GRIFFITH D, MCKINLEY A, PATTERSON J, PRESNELL A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012; 18: 4375-84. http://dx.doi. org/10.1158/1078-0432.CCR-12-0625
45. CASSIER PA, FUMAGALLI E, RUTKOWSKI P, SCHOFFSKI P, VAN GLABBEKE M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012; 18: 4458-64. http://dx.doi. org/10.1158/1078-0432.CCR-11-3025
46. LOVATT M, BIJLMAKERS MJ. Stabilisation of β-catenin downstream of T cell receptor signalling. PLoS One. 2010; 5: e12794. http://dx.doi.org/10.1371/iournal.pone.0012794
47. KORSMEYER SJ, GROSS A, HARADA H, ZHA J, WANG K, et al. Death and survival signals determine active/inactive conformations of pro-apoptotic BAX, BAD, and BID molecules. Cold Spring Harb Symp Quant Biol. 1999; 64: 343-50. http://dx.doi.org/10.1101/sqb.1999.64.343
48. WURSTLE ML, LAUSSMANN MA, REHM M. The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res. 2012; 318: 1213-20. http://dx.doi.org/10.1016/j.yexcr.2012.02.013
49. MORGAN DO. The Cell Cycle: Principles of Control. Oxford University Press/New Science Press, Corby (United Kingdom). 2007.